Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Real Time Quote from BATS)

$112.13 USD

112.13
1,112,035

+6.20 (5.85%)

Updated Aug 7, 2025 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is Jazz (JAZZ) Down 18% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.

Zacks Equity Research

Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 6.25% and 3.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?

by Zacks Equity Research

Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend.

Zacks Equity Research

ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally

by Zacks Equity Research

ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.

Zacks Equity Research

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Zacks Equity Research

Why Jazz (JAZZ) Could Beat Earnings Estimates Again

by Zacks Equity Research

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Zacks Equity Research

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

by Zacks Equity Research

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Jazz Enrolls First Patient in Phase II/III Leukemia Study

by Zacks Equity Research

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

Zacks Equity Research

Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC

by Zacks Equity Research

Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC

Debanjana Dey headshot

7 Impressive Growth Stocks to Buy for 2020

by Debanjana Dey

The prospects of growth stocks appear bright for 2020, making the following companies attractive bets.

Zacks Equity Research

Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

5 High Earnings Yield Stocks for a Standout Portfolio

by Zacks Equity Research

If you are not sure whether to invest your money in bonds or stocks, a key parameter that can show you the right direction is earnings yield.

Sumit Singh headshot

Create a Value-Based Portfolio With These 4 Low P/CF Stocks

by Sumit Singh

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

Zacks Equity Research

Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (JAZZ) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Jazz (JAZZ) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Jazz (JAZZ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Kinjel Shah headshot

5 Low Price-to-Book Value Stocks to Buy as 2020 Nears

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

by Zacks Equity Research

Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

Zacks Equity Research

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Buy in December

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Zacks Equity Research

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

by Zacks Equity Research

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com